AZP2006 in Progressive Supranuclear Palsy: A Multi-Centre, Randomized, Phase 2a Trial Assessing Safety and Biomarker Outcomes
Jean‐Christophe Corvol(Centre National de la Recherche Scientifique), Luc Defebvre(Hôpital Roger Salengro), Olivier Defert(CHemProtect (Czechia)), Cecilia Estrella(CHemProtect (Czechia)), Mickaël Alexandre Obadia(Fondation Ophtalmologique Adolphe de Rothschild), Graziella Mangone(Sorbonne Université), Noëlle Callizot(L.Garde (United States)), Aurélien Blondel(CHemProtect (Czechia)), Louise‐Laure Mariani(Centre National de la Recherche Scientifique), Caroline Moreau(Hôpital Européen Georges-Pompidou), Artin Karapet(CHemProtect (Czechia)), Jean‐Philippe Brandel(Broad Institute), Sara Sambin(Université Paris-Est Créteil), Nicolas Carrière(Inserm), Marie Lebouteux(Fondation Ophtalmologique Adolphe de Rothschild), Philippe Verwaerde(CHemProtect (Czechia))
Cited by 0
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy
|The American Journal of Human Genetics|2016|449
Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus
|Journal of Neuroscience|2003|325
Trial of Lixisenatide in Early Parkinson’s Disease
|New England Journal of Medicine|2024|302